Richard Rosenthal
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1447364286
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,609 of the $24,032 with a category attached, or 69.1%. 12 manufacturers reported payments, led by Amgen at 59.2% of the total. Reporting peaked in 2023 at $17,499 and has fallen 90.4% since, to $1,683 in 2025.
Across 46 payments — averaging $522.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Ascendis Pharma Endocrinology Inc$7K
- AstraZeneca$2K
- Medtronic$160
- Dexcom, Inc.$153
- Amarin Pharma, Inc.$129
- plus $454 from 6 others
What the payments were for
- Consulting fees$2,39210%
- Speaking & faculty fees$16,60969%
- Travel & lodging$2,91512%
- Food & beverage$2,1179%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 22 | $14,238 |
| Ascendis Pharma Endocrinology Inc | 9 | $7,328 |
| AstraZeneca | 4 | $1,569 |
| Medtronic | 2 | $160 |
| Dexcom, Inc. | 2 | $153 |
| Amarin Pharma, Inc. | 1 | $129 |
| Merck | 1 | $114 |
| Amryt Pharma Holdings Ltd | 1 | $85 |
| Xeris Pharmaceuticals, Inc. | 1 | $83 |
| Boehringer Ingelheim | 1 | $82 |
| Novo Nordisk | 1 | $75 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$13,781
- Strensiq$1,549
- Prolia$175
- MINIMED 780G$146
- Vascepa$129
- DEXCOM G7 GSS (161)$120
- STEGLATRO$114
How this compares
$24,032 in reported general payments places this provider in the 75th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 87 | $108,061 |
| TrulicityDulaglutide | 79 | $81,904 |
| JardianceEmpagliflozin | 63 | $70,307 |
| OzempicSemaglutide | 37 | $49,535 |
| TradjentaLinagliptin | 34 | $20,435 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $15,720 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $15,308 |
| Victoza 3-PakLiraglutide | 15 | $14,797 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $12,554 |
| SynthroidLevothyroxine Sodium | 119 | $12,246 |
| JanuviaSitagliptin Phosphate | 14 | $11,955 |
| Levothyroxine Sodium | 440 | $9,230 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $8,657 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $7,492 |
| Novolog FlexpenInsulin Aspart | 31 | $5,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $82 | $90,74297 claims |
| Novo NordiskOzempic, Novolog | $75 | $54,90851 claims |
| MerckJanuvia | $114 | $11,95514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
- Malek KarassiBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.